Hongtao Liu

Hongtao Liu

Auto-generated profile, based on publicly available information

Hongtao Liu

Institute of Molecular Biology and Biophysics, ETH Zürich, Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHongtao Liu
Hongtao Liu
DZDariusz Zakrzewicz
Dariusz Zakrzewicz
KNKamil Nosol
Kamil Nosol
RIRossitza N. Irobalieva
Rossitza N. Irobalieva
SMSomnath Mukherjee
Somnath Mukherjee
KLKaspar P. Locher
Kaspar P. Locher
Cellular entry of the hepatitis B and D viruses (HBV/HDV) requires binding of the viral surface polypeptide preS1 to the hepatobiliary transporter Na+-taurocholate co-transporting polypeptide (NTCP). This interaction can be blocked by bulevirtide (BLV, formerly Myrcludex B), a preS1 derivative and approved drug for treating HDV infection. Here, to elucidate the basis of this inhibitory function, we determined a cryo-EM structure of BLV-bound human NTCP. BLV forms two domains, a plug lodged in the bile salt transport tunnel of NTCP and a string that covers the receptor’s extracellular surface. The N-terminally attached myristoyl group of BLV interacts with the lipid-exposed surface of NTCP. Our structure reveals how BLV inhibits bile salt transport, rationalizes NTCP mutations that decrease the risk of HBV/HDV infection, and provides a basis for understanding the host specificity of HBV/HDV. Our results provide opportunities for structure-guided development of inhibitors that target HBV/HDV docking to NTCP.

10 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHongtao Liu
Hongtao Liu
RIRossitza N. Irobalieva
Rossitza N. Irobalieva
JKJulia Kowal
Julia Kowal
DNDongchun Ni
Dongchun Ni
KNKamil Nosol
Kamil Nosol
KLKaspar P. Locher
Kaspar P. Locher
BSEP (ABCB11) is an ATP-binding cassette transporter that is expressed in hepatocytes and extrudes bile salts into the canaliculi of the liver. BSEP dysfunction, caused by mutations or induced by drugs, is frequently associated with severe cholestatic liver disease. We report the cryo-EM structure of glibenclamide-bound human BSEP in nanodiscs, revealing the basis of small-molecule inhibition. Glibenclamide binds the apex of a central binding pocket between the transmembrane domains, preventing BSEP from undergoing conformational changes, and thus rationalizing the reduced uptake of bile salts. We further report two high-resolution structures of BSEP trapped in distinct nucleotide-bound states by using a catalytically inactivated BSEP variant (BSEPE1244Q) to visualize a pre-hydrolysis state, and wild-type BSEP trapped by vanadate to visualize a post-hydrolysis state. Our studies provide structural and functional insight into the mechanism of bile salt extrusion and into small-molecule inhibition of BSEP, which may rationalize drug-induced liver toxicity.

6 February 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
GHGong He
Gong He
TKTheodore Karrison
Theodore Karrison
WSWendy Stock
Wendy Stock
RLRichard A. Larson
Richard A. Larson
SKSatyajit Kosuri
Satyajit Kosuri
HLHongtao Liu
Hongtao Liu

22 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HLHongtao Liu
Hongtao Liu
DZDariusz Zakrzewicz
Dariusz Zakrzewicz
KNKamil Nosol
Kamil Nosol
RIRossitza N. Irobalieva
Rossitza N. Irobalieva
SMSomnath Mukherjee
Somnath Mukherjee
KLKaspar P. Locher
Kaspar P. Locher
Cellular entry of the hepatitis B and D viruses (HBV/HDV) require binding of the viral surface polypeptide preS1 to the hepatobiliary transporter NTCP. This interaction can be blocked by bulevirtide (BLV, formerly Myrcludex B), a preS1 derivative and approved drug for treating HDV infection. To elucidate the basis of this inhibitory function, we determined a cryo-EM structure of BLV-bound human NTCP. BLV forms two domains, a plug lodged in the bile salt transport tunnel of NTCP and a string that covers the receptor’s extracellular surface. The N-terminally attached myristoyl group of BLV interacts with the lipid-exposed surface of NTCP. Our structure reveals how BLV inhibits bile salt transport, rationalizes NTCP mutations that decrease the risk of HBV/HDV infection, and provides a basis for understanding the host specificity of HBV/HDV. Our results provide opportunities for structure-guided development of inhibitors that target HBV/HDV docking to NTCP.